Luminex logo

LMNX - Luminex News Story

$36.66 0.0  0.0%

Last Trade - 14/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.23bn
Enterprise Value £1.22bn
Revenue £311.5m
Position in Universe 2333rd / 6851

BUZZ-Luminex: Jefferies sees improved 2020 core revenue growth on new product launches

Tue 11th February, 2020 4:33pm
** Shares of biological testing tools maker  LMNX.O  rise
~6% to $24.99
    ** Company's Q4 profit beat estimates on Monday, driven by
growth in molecular sample-to-answer business  urn:newsml:reuters.com:*:nPn8yw8fTa
    ** Analysts at Jefferies say revenue growth in first half of
2020 will be muted, but LMNX is poised to improve its core
revenue growth in second half driven by new product launches
including Verigene 2, Intelliflex, and Guava benchtop flow
cytometry system
    ** Brokerage maintains "hold" rating and PT of $22
    ** Co's Q4 revenue rose 12% to $90.5 mln compared with a
year earlier; LMNX forecast 2020 full-year revenue to be in
range of $352 mln-$362 mln



 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com ; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.